Clinical Trials Browser

Phase 1/2 × Wilms Tumor × atezolizumab × Clear all

NCT05765084 2024-05-16

Immuno-MESODEC

Phase 1/2 Recruiting

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Wilms Tumor